ATR inhibitor AZD6738 (ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib
Published date:
01/25/2022
Excerpt:
In a BRCA2-mutant patient-derived triple-negative breast cancer (TNBC) xenograft model, complete tumor regression was achieved with 3-5 days of daily AZD6738 per week concurrent with olaparib....These preclinical data provide rationale for clinical evaluation of AZD6738 as a monotherapy or combinatorial agent.